Caris Life Sciences, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-negative breast cancer. Caris GPSai®, the com
Caris Life Sciences (NasdaqGS:CAI) published a pivotal study on its Caris Lookback Program confirming its effectiveness in finding patients eligible for newly approved targeted therapies. The company released new evidence that Whole Exome Sequencing supports more robust tumor mutational burden assessment for immunotherapy eligibility. Caris also recently launched Caris MI Clarity, an AI driven test aimed at assessing breast cancer recurrence risk. For investors watching precision oncology,...
Caris Life Sciences (NasdaqGS:CAI) published a pivotal study on its Caris Lookback Program confirming its effectiveness in finding patients eligible for newly approved targeted therapies. The company released new evidence that Whole Exome Sequencing supports more robust tumor mutational burden assessment for immunotherapy eligibility. Caris also recently launched Caris MI Clarity, an AI driven test aimed at assessing breast cancer recurrence risk. For investors watching precision oncology,...
Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.
Stanley Druckenmiller is one of the most-watched money managers on Wall Street, and his Duquesne Family Office Q1 2026 13F filing just landed. The headline number is brutal for Alphabet bulls. Duquesne sold all 385,000 shares of Alphabet (GOOGL) Class A stock during the quarter. That same stake had ...
Stanley Druckenmiller is one of the most-watched money managers on Wall Street, and his Duquesne Family Office Q1 2026 13F filing just landed. The headline number is brutal for Alphabet bulls. Duquesne sold all 385,000 shares of Alphabet (GOOGL) Class A stock during the quarter. That same stake had ...
Investor Stanley Druckenmiller’s Duquesne Family Office exited a 385,000 share position in Alphabet in the first quarter.
Investor Stanley Druckenmiller’s Duquesne Family Office exited a 385,000 share position in Alphabet in the first quarter.
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies.
Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with previously identified
Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June. Speaking at an investor conference, a Caris executive identified by Chief Scientific
Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June. Speaking at an investor conference, a Caris executive identified by Chief Scientific
Caris Life Sciences, Inc. (CAI) Bank of America Global Healthcare Conference 2026 May 12, 2026 1:00 PM EDTCompany ParticipantsBrian Brille - Executive Vice...
Presenter SpeechMichael Ryskin Bobby Hill, Senior Vice President and C-CEO; and then finally, Luke Power, CFO from Caris. The recent the IPO-ed less than a year ago, and we'll have a presentation.
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembroliz
In early May 2026, Caris Life Sciences reported first‑quarter revenue of US$216.17 million versus US$120.92 million a year earlier, with net loss narrowing to US$0.51 million from US$102.58 million, alongside launches of the AI-based Caris MI Clarity breast cancer prognostic test and MolDX-approved Caris ChromoSeq whole genome assay for myeloid malignancies. These results highlight how Caris is pairing rapid financial progress with new AI and whole genome diagnostics that could broaden...
In early May 2026, Caris Life Sciences reported first‑quarter revenue of US$216.17 million versus US$120.92 million a year earlier, with net loss narrowing to US$0.51 million from US$102.58 million, alongside launches of the AI-based Caris MI Clarity breast cancer prognostic test and MolDX-approved Caris ChromoSeq whole genome assay for myeloid malignancies. These results highlight how Caris is pairing rapid financial progress with new AI and whole genome diagnostics that could broaden...
Caris Life Sciences stock snapshot Caris Life Sciences (CAI) has caught investor attention after recent price moves, with the stock last closing at $19.84. That price sits against mixed short term returns and a sizeable year to date decline. See our latest analysis for Caris Life Sciences. Recent trading has brought a modest short term lift, with a 1 day share price return of 3.71% and a 30 day share price return of 5.81%, but that sits against a 26.46% year to date share price decline,...
Caris Life Sciences stock snapshot Caris Life Sciences (CAI) has caught investor attention after recent price moves, with the stock last closing at $19.84. That price sits against mixed short term returns and a sizeable year to date decline. See our latest analysis for Caris Life Sciences. Recent trading has brought a modest short term lift, with a 1 day share price return of 3.71% and a 30 day share price return of 5.81%, but that sits against a 26.46% year to date share price decline,...
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 30.79M | $550.45M | 0.03% | Added+116.5% | 2026-03-31 |
| Coatue | growth | 9.82M | $175.58M | 0.60% | Unchanged | 2026-03-31 |
| StateStreet | passive | 985.0K | $17.61M | 0.00% | Added+277.9% | 2026-03-31 |
| Citadel | multi-strat | 918.3K | $16.42M | 0.02% | Trimmed-50.8% | 2026-03-31 |
| RenTech | quant | 449.9K | $8.04M | 0.01% | Added+36.4% | 2026-03-31 |
| DEShaw | quant | 129.6K | $2.32M | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 4.37M | $78.17K | 0.01% | Trimmed-9.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | 0.02 | — | — |
| 2026-05-07 | -0.02 | — | +100.00% |
| 2026-02-26 | 0.10 | 0.28 | +168.69% |
| 2025-11-05 | -0.14 | 0.08 | +158.83% |
| 2025-08-12 | -0.22 | -1.11 | -411.18% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CAI | -9.47% | -13.73% | -38.03% | — |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -12.44% | -9.09% | -34.59% | — |